SCHEMBL21722983

SCHEMBL21722983

CCOC(=O)c1ccc(NC(C)=O)c(Cl)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.64
ALDH1A1 P00352 4/20 0.56
RAB9A P51151 4/20 0.53
CYP1A2 P05177 2/20 0.53
SMN1; SMN2 Q16637 4/20 0.51
NPC1 O15118 3/20 0.51
KDM4E B2RXH2 2/20 0.51
STAT1 P42224 1/20 0.51
POLB P06746 1/20 0.51
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA9 Q16790 2/20 0.50
CA12 O43570 1/20 0.50
CA7 P43166 1/20 0.50
CA14 Q9ULX7 1/20 0.50
LMNA P02545 1/20 0.49
CYP3A4 P08684 1/20 0.49
MAOA P21397 1/20 0.49
MEN1 O00255 1/20 0.47
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Toluene SCHEMBL27493073 0.92 KMT2A (0.56) KMT2AALDH1A1RAB9ACYP1A2SMN1; SMN2
SCHEMBL1459457 0.88 ALDH1A1 (0.73) KMT2AALDH1A1RAB9ACYP1A2SMN1; SMN2
SCHEMBL5682954 0.85 KMT2A (0.67) KMT2AALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL8856939 0.85 CA12 (0.53) KMT2AALDH1A1RAB9ACYP1A2NPC1
SCHEMBL27783040 0.85 CA12 (0.53) KMT2AALDH1A1RAB9ACYP1A2NPC1
SCHEMBL27915444 0.85 RAB9A (0.50) KMT2AALDH1A1RAB9ACYP1A2NPC1
SCHEMBL8816442 0.85 RAB9A (0.62) KMT2AALDH1A1RAB9ACYP1A2SMN1; SMN2
SCHEMBL28680863 0.84 ALDH1A1 (0.77) KMT2AALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL8319324 0.84 RAB9A (0.64) KMT2AALDH1A1RAB9ACYP1A2SMN1; SMN2
SCHEMBL29097191 0.84 KMT2A (0.65) KMT2AALDH1A1RAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3837008-B1 SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY PHARMACYL AB (SE) 2025-09-24 EP disclosed
CN-112703036-B Substituted benzamides and their use in therapy 法玛西尔有限公司 2025-05-27 CN disclosed
US-20250064761-A1 SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY PHARMACYL AB (SE) 2025-02-27 US disclosed
CN-112770736-B Novel medical treatment of pathological inflammation 法玛西尔有限公司 2025-01-21 CN disclosed
EP-3836912-B1 COMBINATIONS OF SUBSTITUTED BENZAMIDES AND 5-ASA AGENTS PHARMACYL AB (SE) 2024-05-01 EP disclosed
US-11896564-B2 Medical treatment for pathologic inflammation PHARMACYL AB (SE) 2024-02-13 US disclosed
US-11717500-B2 Treatment of spondyloarthritis PHARMACYL AB (SE) 2023-08-08 US disclosed
US-20220087959-A1 A NEW MEDICAL TREATMENT FOR PATHOLOGIC INFLAMMATION PHARMACYL AB (SE) 2022-03-24 US disclosed
US-20210299071-A1 SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY PHARMACYL AB (SE) 2021-09-30 US disclosed
US-20210236441-A1 TREATMENT OF SPONDYLOARTHRITIS PHARMACYL AB (SE) 2021-08-05 US disclosed
EP-3837008-A2 SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY Pharmacyl AB (SE) 2021-06-23 EP disclosed
EP-3836912-A1 A NEW MEDICAL TREATMENT FOR PATHOLOGIC INFLAMMATION Pharmacyl AB (SE) 2021-06-23 EP disclosed
CN-112770736-A Novel medical treatment of pathological inflammation 法玛西尔有限公司 2021-05-07 CN disclosed
CN-112703036-A Substituted benzamides and their use in therapy 法玛西尔有限公司 2021-04-23 CN disclosed
WO-2020035554-A1 A NEW MEDICAL TREATMENT FOR PATHOLOGIC INFLAMMATION PHARMACYL AB (SE) 2020-02-20 WO disclosed
WO-2020035555-A2 SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY PHARMACYL AB (SE) 2020-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11896564-B2 Medical treatment for pathologic inflammation KIT, IL5, IL6 KMT2A 3398/4885ALDH1A1 71/4885RAB9A 3779/4885
US-20250064761-A1 SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY BRD4, SI, BRD7 KMT2A 1087/4885ALDH1A1 719/4885RAB9A 2183/4885
US-11717500-B2 Treatment of spondyloarthritis SPAST, IL17A, SLC10A2 KMT2A 4069/4885ALDH1A1 1318/4885RAB9A 3803/4885
US-20210236441-A1 TREATMENT OF SPONDYLOARTHRITIS SPAST, IL17A, SLC10A2 KMT2A 4069/4885ALDH1A1 1318/4885RAB9A 3803/4885
US-20220087959-A1 A NEW MEDICAL TREATMENT FOR PATHOLOGIC INFLAMMATION KIT, IL5, IL1B KMT2A 3444/4885ALDH1A1 73/4885RAB9A 3724/4885
US-20210299071-A1 SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY BRD4, SI, BRD7 KMT2A 1087/4885ALDH1A1 719/4885RAB9A 2183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.